Compare M&T Bank Corporation (MTB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? M&T Bank Corporation trades at $248.99 (market cap $36.15B), while Vertex Pharmaceuticals Incorporated trades at $478.01 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.4× M&T Bank Corporation's market cap, and M&T Bank Corporation pays a 2.41% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MTB | VRTX | |
|---|---|---|
Market Cap | $36.15B | $121.95B |
Sector | Financials | Health |
52-Week High | $254.04 | $529.59 |
52-Week Low | $178.63 | $366.54 |
Dividend Yield | 2.41% | — |
Enterprise Value | — | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
